Technology
Health
Biotechnology

Celldex

$4.81
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.20 (-3.89%) Today
-$0.13 (-2.63%) After Hours

Why Robinhood?

You can buy or sell Celldex and other stocks, options, ETFs, and crypto commission-free!

About

Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates include Varlilumab, CDX-1140, and CDX-301, and CDX-3379. Read More The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Employees
137
Headquarters
Hampton, New Jersey
Founded
1983
Market Cap
59.07M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
213.28K
High Today
$5.21
Low Today
$4.85
Open Price
$5.13
Volume
168.25K
52 Week High
$37.20
52 Week Low
$2.75

Collections

Technology
Health
Biotechnology
Therapy
Biopharmaceutical
Pharmaceutical
US
North America

News

Yahoo FinanceMar 8

Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat

Celldex Therapeutics, Inc. CLDX incurred adjusted loss of 95 cents per share in fourth-quarter 2018, narrower than the Zacks Consensus Estimate of a loss of $1.20 and the year-ago loss of $2.55. The loss has been adjusted for a gain of $1.65 million on fair value re-measurement of contingent consideration. However, including the fair value re-measurement item, the reported loss was 81 cents compared with a loss of 42 cents in the year-ago quarter. Total revenues in the quarter declined 49% year over year t...

582
The Motley FoolMar 8

Celldex Therapeutics' Cost-Cutting and Reverse Stock Split Help Keep It Rolling

Celldex Therapeutics (NASDAQ:CLDX) is in a much different place than it was one year ago. The biotech continues to feel the repercussions from the failure of glembatumumab vedotin (glemba) in the Metric clinical study targeting the treatment of triple-negative breast cancer. But just as Celldex plugged away in the third quarter, the company kept moving forward in the fourth quarter, as well. Celldex provided an update of its fourth-quarter performance after the market closed on Thursday. Here are the highl...

590
Seeking AlphaMar 7

Celldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q4 2018 Results - Earnings Call Transcript

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Q4 2018 Results Earnings Conference Call March 7, 2019 4:30 PM ET Company Participants Sarah Cavanaugh - Senior Vice President, Corporate Affairs and Administration Anthony Marucci - Co-Founder, President, Chief Executive Officer Tibor Keler - Co-Founder, Executive Vice President, and Chief Scientific Officer Sam Martin - Senior Vice President and Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Good day, ladies a...

17

Earnings

-$1.20
-$0.81
-$0.43
-$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.